Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fenretinide for insulin sensitivity in obese insulin-resistant postmenopausal women
NL-OMON25232Recruiting
- Sponsor
- Academic Medical Center
- Start
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of fenretinide in insulin resistance (IR), obesity, cardiometabolic risk (CMR) and 1 more (2 arms), sponsored by Academic Medical Center. Primary endpoints: Change in hepatic insulin sensitivity and Change in peripheral insulin sensitivity. Started Oct 2012; status: recruiting.
02
Drugs
fenretinide
03
Conditions
insulin resistance (IR)obesitycardiometabolic risk (CMR)steatosis
Beyond the preview
Go deeper on NL-OMON25232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON25232.